Key features and details
- Syrian hamster monoclonal [MR1] to TRAP/CD40L (PE)
- Suitable for: IP, Flow Cyt, Blocking
- Reacts with: Mouse
- Conjugation: PE. Ex: 488nm, Em: 575nm
- Isotype: IgG
Product nameAnti-TRAP/CD40L antibody [MR1] (PE)
See all TRAP/CD40L primary antibodies
DescriptionSyrian hamster monoclonal [MR1] to TRAP/CD40L (PE)
Host speciesSyrian hamster
ConjugationPE. Ex: 488nm, Em: 575nm
Tested applicationsSuitable for: IP, Flow Cyt, Blockingmore details
Species reactivityReacts with: Mouse
Tissue, cells or virus corresponding to Mouse TRAP/CD40L. Activated mouse Th1 clone D1.6
ab25568 binds to murine CD40L with high affinity, blocks binding to CD40, and blocks CD40L function. Administration of this antibody to mice blocks the ability to mount primary and secondary immune responses to TD antigens, yet does not alter the immune response to TI antigens.
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferpH: 7.20
Preservative: 0.09% Sodium azide
Constituents: 0.14% Monobasic dihydrogen sodium phosphate, 0.87% Sodium chloride, 0.1% Gelatin
Also contains a stabilizing agent.
Concentration information loading...
Primary antibody notesab25568 binds to murine CD40L with high affinity, blocks binding to CD40, and blocks CD40L function. Administration of this antibody to mice blocks the ability to mount primary and secondary immune responses to TD antigens, yet does not alter the immune response to TI antigens.
Light chain typekappa
Our Abpromise guarantee covers the use of ab25568 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at an assay dependent concentration.|
|Flow Cyt||Use at an assay dependent concentration.|
|Blocking||Use at an assay dependent concentration.
In vivo and In vitro blocking of CD40L.
FunctionMediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL-4. Involved in immunoglobulin class switching.
Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, actin polymerization, and an matrix metalloproteinases (MMP) inhibitor-sensitive pathway.
Tissue specificitySpecifically expressed on activated CD4+ T-lymphocytes.
Involvement in diseaseDefects in CD40LG are the cause of X-linked immunodeficiency with hyper-IgM type 1 (HIGM1) [MIM:308230]; also known as X-linked hyper IgM syndrome (XHIM). HIGM1 is an immunoglobulin isotype switch defect characterized by elevated concentrations of serum IgM and decreased amounts of all other isotypes. Affected males present at an early age (usually within the first year of life) recurrent bacterial and opportunistic infections, including Pneumocystis carinii pneumonia and intractable diarrhea due to cryptosporidium infection. Despite substitution treatment with intravenous immunoglobulin, the overall prognosis is rather poor, with a death rate of about 10% before adolescence.
Sequence similaritiesBelongs to the tumor necrosis factor family.
modificationsThe soluble form derives from the membrane form by proteolytic processing.
N-linked glycan is a mixture of high mannose and complex type. Glycan structure does not influence binding affinity to CD40.
Cellular localizationSecreted and Cell membrane.
- Information by UniProt
- CD 40L antibody
- CD154 antibody
- CD40 antigen ligand antibody
ab25568 has been referenced in 1 publication.
- Lei L et al. CD40L-adjuvanted DNA vaccine carrying EBV-LMP2 antigen enhances anti-tumor effect in NPC transplantation tumor animal. Cent Eur J Immunol 43:117-122 (2018). PubMed: 30135622